Aged 56, François Miceli holds a degree in biological engineering from the University of Paris XII – UPEC, is an alumnus of INSEAD (Corporate Finance, EE) and an auditor at IHEDN (Institut des Hautes Etudes de Défense Nationale, promotion Chevalier Bayard). He began his career at CLONATEC, an OHF group listed on the second market (now Euronext Growth), one of the very first biotech companies in France, where he held the position of product manager at the international level.
At the end of 1990, he joined IDEXX Laboratories Incorporated, an American company listed on NASDAQ, where he successively held the positions of Director Europe, Asia, Africa and Middle East of a business unit, then Managing Director of the French subsidiary IDEXX France S.A. and finally Managing Director and member of the Board of Directors of the Italian subsidiary IDEXX Laboratories Italia. During all these years spent within IDEXX, François Miceli was a member of the European Executive Committee.
In 1998, he joined SYNBIOTICS, a spin-off of Laboratoires MERIAL, as Director of International Operations before participating in the creation of LMD Pharma, a biotechnology start-up alongside venture capital funds, Banexi Ventures, LCF Rothschild, Siparex and Sofimac Partners Capital Investissement.
From October 2003 to February 2011, François was Chairman of the Board of Directors of the IMAXIO group, which specializes in infectious diseases (vaccines) and oncology, based in Lyon and Clermont-Ferrand. Since February 2009, he was also President and CEO of AXCELL Biotechnologies, a subsidiary of Imaxio. Under his presidency, IMAXIO won successively the 3rd Deloitte Fast 50 – Rhône-Alpes award in 2009 and the 2nd Deloitte Fast 50 – Rhône-Alpes award in 2010. Within the framework of the IMAXIO group, François Miceli was also Manager of EDULIS Technologie, a holding company for the management of technological assets of the Imaxio group.
After having been a Venture Partner and a member of the investment committee, François MICELI fully joined the private equity firm SOFIMAC PARTNERS in 2012 as Senior Partner. Managing Partner of SOFIMAC INNOVATION, a management company with 400 million euros in innovation capital. The latter has just merged with UI Investissement in which François is Senior Associate Director for Innovation.
François is also a director of Exeliom Biosciences, Ixaltis, Eurekam, Diabeloop, Igyxos, Axoltis, Aptys Pharmaceuticals, Cellmade, Isorg, Precilens and Futuragaia.
He is also a member of the Board of Directors of the M2CARE gas pedal specialized in health and nutrition and was President of the SAS INSERM TRANSFERT INITIATIVE
Until May 2009, François Miceli chaired the Supervisory Board ofERYtech Pharma S.A . listed on Euronext and he is a former administrator of the SIMV (Syndicat de l’Industrie du Médicament Vétérinaire). He is also AMF certified.